We are a clinical stage oncology therapeutics company developing a paradigm shift in regards to the treatment of cancer

  • Lead Product Candidate – ATI01, is entering Phase II clinical development for NSCL cancer.

  • Ongoing Product Development – Pipeline of drug candidates targeting pancreatic, ovarian and colon.

  • Treatment Efficacy – Targeting metabolic dysfunction avoids the pitfalls of the broad toxicity of platinum-based therapies, enhances the cancer cells sensitivity to chemotherapy & immunotherapy and enhances p53 mediated cellular apoptosis in cancer cells.

  • Experienced Leadership – 100 years of combined pharma experience and 20 products commercialized including two of the best selling oncology drugs, Avastin and Tarceva.

  • Performance History – Over 1,200 patients safely and effectively treated in the U.S., Australia and South Africa.

The Problem – Targeting cancers with high mortality and limited treatment options

Meet Our Team

Michael HandleyCEO
Successful pharmaceutical executive with over 17 products commercialized, including industry leading oncology drugs, and two successful exits in excess of $1.2B. Both public and private company experience.
Andy WhiteCFO
Over 20 years of experience in the healthcare and biomedical industries. Experience includes management of health system contracts, cardio-pulmonary products, orthopedic products, SaaS software, and biopharmaceuticals.
Scott Dunbar M.D.Medical Advisor
Successful Dartmouth trained medical oncologist and hematologist with over 16 years of clinical practice experience. Helped to grow the largest privately held oncology practice in the US.
Victoria Headley J.D. LLMLegal Advisor
An accomplished senior corporate counsel with significant experience handling corporate, transaction and intellectual property matters both domestically and internationally. Also possesses three law degrees and extensive experience in the healthcare sector.

Meet Our Board of Directors

Peter LangeBoard Member
Mr. Lange was one of the Co-founders of Reven pharmaceuticals and helped build the management team that currently drives the company. He has over 35 years of Executive Management experience, 18 of which have been in the biotech/pharmaceutical industry.
Michael VolkBoard Member
Mr. Volk is known as a creator. He has consulted with or started over 200 companies including Reven. He has 24 years of International Executive Management experience, 20 of which have been in Healthcare, Pharmaceuticals, and Biotech. His specific areas of expertise are in operations and finance. He has taken companies public and been involved in several complex financial transactions to help companies create a sound capital structure.
Brian DenommeBoard Member
Mr. Denomme is a Co-Founder of Reven Pharmaceuticals with 30 years of International Executive Management experience, over half of which have been in the biotech/pharmaceutical industry.Mr. Denomme’s communication skills, coupled with his ability to work with international standards and regulations, make him uniquely qualified to lead Reven’s global operations. He leverages his background to oversee the company’s manufacturing and operations with direct oversight of Reven’s strategic direction and legal projects.
Andy WhiteBoard Member
Over 20 years of experience in the healthcare and biomedical industries. Experience includes management of health system contracts, cardio-pulmonary products, orthopedic products, SaaS software, and biopharmaceuticals.
Michael HandleyBoard Member
Successful pharmaceutical executive with over 17 products commercialized, including industry leading oncology drugs, and two successful exits in excess of $1.2B. Both public and private company experience.

“We are constantly discovering and innovating to make a meaningful impact for the patients we serve. We are pushing the boundaries on what science and technology can do, making the impossible, possible.”

PETER LANGE, DIRECTOR

ATI01

Lead product candidate for NSCL cancers

Our Solution

We targeting oncological metabolic dysfunction as a strategy for selective cellular apoptosis

Product Pipeline

Initially targeting four cancers that have poor outcomes and an unmet medical need

About Us

Experienced management team whom developed and launched multiple oncology therapies